Role of anthracyclines and taxanes in TN breast cancer Efficacy results of anthracycline-based regimens in patients with TNBC remain controversial. The analysis from the MA5 study (which randomized patients between CMF and FEC), showed an increased 5-year DFS in favor of CMF (71% vs 51%) in the basal-like subtype group. The test for interaction between biologic phenotype and treatment arm almost reached significance (p=0,06) indicating that patients with TNBC may not derive a particular benefit from anthracyclines.